Can I read Dose-fractionation Sensitivities of Low/Middle/High-risk Prostate Cancer Deduced from Seven International Primary Institutional Datasets on EtoBox?

Dose-fractionation Sensitivities of Low/Middle/High-risk Prostate Cancer Deduced from Seven International Primary Institutional Datasets by R. Miralbell; S.A. Roberts; E. Zubizarreta; J.H. Hendry is a Medicine article available to read on EtoBox.

What is Dose-fractionation Sensitivities of Low/Middle/High-risk Prostate Cancer Deduced from Seven International Primary Institutional Datasets about?

not correlate with outcome (p = 0.63, 0.71, 0.96, respectively). To date, 8 patients have failed biochemically, but 3 were within the first 4 months of follow-up. Conclusions: Toxicities have been acceptable and similar across all HPFX levels, consistent with the a/b of 3 assumed for late effects when the study was planned. Furthermore, actuarial bPFS rates at 3-5 years are high, comparable to expectations with dose-escalated standard fractionation. With further follow-up, this stepwise study may provide a solid basis for further reduction in fraction number. Hypofractionation currently remains investigational, but If validated by currently ongoing trials, the potential exists for significant therapeutic gain as well as substantial health care cost and utilization advantages in the treatment of prostate cancer.

Who reads Dose-fractionation Sensitivities of Low/Middle/High-risk Prostate Cancer Deduced from Seven International Primary Institutional Datasets?

Author

R. Miralbell; S.A. Roberts; E. Zubizarreta; J.H. Hendry

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0360-3016)

Published

2009

Language

EN

Field

Medicine (Health Sciences)